Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials. - Wikidata - wikimedia - TriplyDB

Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials.

Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials.

http://www.wikidata.org/entity/Q36128551

about

Therapeutic potential of PDE modulation in treating heart disease Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration Advances in targeting cyclic nucleotide phosphodiesterases Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy.Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials.Right ventricular cyclic nucleotide signaling is decreased in hyperoxia-induced pulmonary hypertension in neonatal mice.Transcriptional and post-transcriptional regulation of cGMP-dependent protein kinase (PKG-I): pathophysiological significance Left ventricular dysfunction with pulmonary hypertension: part 2: prognosis, noninvasive evaluation, treatment, and future research.Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts.Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction.Erectile dysfunction drugs and oxidative stress in the liver of male rats Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy.Effects of chronic administration of the phosphodiesterase inhibitor vardenafil on serum levels of adrenal and testicular steroids in men with type 2 diabetes mellitus.

P2860

Q27005761-DCEA7C4A-A218-42CC-BDA6-E4E0ABC4E336 Q28068468-BC1D6277-7324-400F-9893-30095842EA36 Q34139490-3959CBEF-9771-47C1-A17C-F65EDFDBC51F Q34315276-A7A3F6A6-3A9B-4E40-B0FA-57A84C84E59D Q34364927-ABB0849B-D686-4B3D-9E97-CA737B4C89F3 Q35749616-4F6E3C41-9351-4C32-8CDF-93313CE3E2AB Q36529020-8D5B15F6-29CD-42B7-8FC4-372F8D07F1AB Q36868978-9EAE629E-5439-45FF-8354-5A97514A68C9 Q37240478-DF668AEC-BB1A-4D2F-99A3-4A0D76EA6466 Q38542767-F077AC4E-6FFB-443B-B96F-D8332E96162E Q41025346-95976902-48EF-4C80-8437-5BFC3955860F Q41680225-ACD58591-15F9-4323-B2E9-D5E19F4C7D65 Q41819549-52FA9B90-7914-41CD-B4C8-BA086E975AB2 Q48115926-A94B0898-BDAD-45EC-BC5F-5032C5C87F94

P2860

Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials.

http://www.wikidata.org/entity/Q36128551

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Cardiac role of cyclic-GMP hyd ...... tal models to clinical trials.

@ast

Cardiac role of cyclic-GMP hyd ...... tal models to clinical trials.

@en

type

label

Cardiac role of cyclic-GMP hyd ...... tal models to clinical trials.

@ast

Cardiac role of cyclic-GMP hyd ...... tal models to clinical trials.

@en

prefLabel

Cardiac role of cyclic-GMP hyd ...... tal models to clinical trials.

@ast

Cardiac role of cyclic-GMP hyd ...... tal models to clinical trials.

@en

P1433

Q36128551-150723A2-9811-4B9B-A5EB-EDD2A96830A5

P1476

Q36128551-657BFE9F-E3CB-4FAE-8BCD-B98E0A086C67

P2093

Q36128551-9ADAB19D-F17D-4ABB-A6ED-D0950D1ADB53

P2860

Q36128551-01658888-F0BE-4C74-AA78-2577AD1DE4FB

Q36128551-07BFFA0A-4611-4733-B773-2A12CC8FF4C7

Q36128551-166DC1EE-0892-40DF-A73D-A6FBD545E5EF

Q36128551-218063CB-33D1-4876-B128-FD99B21BBAE8

Q36128551-231409CD-5349-44BB-A9E7-62FA61DDF35E

Q36128551-24C18842-9500-4C73-B198-9260509E0F32

Q36128551-2A8A7669-4414-4AB9-955A-4565ACD1A659

Q36128551-372A842C-4859-42AC-9AAF-96A0F7CEA545

Q36128551-373E38D2-3217-47A5-ABF9-122708A3D046

Q36128551-384F4607-4FCA-4A77-B5EE-0BEAD569F756

P2888

Q36128551-7D312BDA-61F9-4872-B306-E62B95D0999E

P304

Q36128551-951EC5E0-3BE5-4870-BD0C-CA9B41B2FF5A

P31

Q36128551-F1D76A2D-D403-4000-B4D2-1A19EFA53712

P356

Q36128551-27697052-7910-4FCD-B856-F4245E6605EC

P433

Q36128551-31919129-F0D0-4AC0-9935-3EDB3876CB55

P478

Q36128551-DD7C3AFC-34B1-4AD8-BFAA-C70B3F44AB64

P577

Q36128551-52BA4B79-A4B8-466D-B924-D2B7C7E64339

P698

Q36128551-1F29BDB2-BE93-4E7C-9B19-93BBF202C921

P932

Q36128551-9948A89E-7B3F-4337-BA52-DD57A0434551

P356

S11897-012-0101-0

P1433

Current heart failure reports

P1476

Cardiac role of cyclic-GMP hyd ...... tal models to clinical trials.

@en

P2093

David A Kass

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphodiesterases and cardiac cGMP: evolving roles and controversies

Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use

Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility

Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart

PDE5 is converted to an activated state upon cGMP binding to the GAF A domain

Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice

cGMP Signals Modulate cAMP Levels in a Compartment-Specific Manner to Regulate Catecholamine-Dependent Signaling in Cardiac Myocytes

PDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation.

Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase I

Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.

P2888

s11897-012-0101-0

P304

192-199

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11897-012-0101-0

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22798047

http://www.w3.org/2001/XMLSchema#string

P932

3408604

http://www.w3.org/2001/XMLSchema#string